Entero Therapeutics, Inc. filed a Form 8-K reporting several exhibits tied to a material corporate action. The company filed a Certificate of Designation establishing Series H Non-Voting Convertible Preferred Stock with the Delaware Secretary of State on October 1, 2025. The filing also lists a Form of Registration Rights Agreement, a Share Exchange Agreement, and a Press Release dated October 1, 2025 as exhibits. The cover page interactive XBRL is included. The Form 8-K is signed by Jason D. Sawyer as Interim Chief Executive Officer on October 6, 2025, indicating the company provided contemporaneous disclosure of these actions.
Document scope and corporate actions: This S-1/A incorporates the company’s 2024 Annual Report on Form 10-K and 10-Qs for March 31, 2025 and June 30, 2025 and states that all historical share and per-share figures reflect a 1-for-3 reverse stock split effective August 18, 2025. The filing lists authorized capital of 100,000,000 common shares and 10,000,000 preferred shares.
Intellectual property and patents: The filing references multiple patent families, including European and U.S. patents for a Yarrowia lipolytica lipase (European expiry June 15, 2026; U.S. expirations Sept 11, 2028 and July 17, 2026) and issued U.S. patents for inflammatory-condition treatments expiring Sept 1, 2036 and patents directed to niclosamide use expiring March 31, 2040.
Other material items: The prospectus lists risks and cost items related to development, regulatory approval, manufacturing, commercialization, patent prosecution and personnel. It discloses selling-stockholder warrant holdings with a 4.9% beneficial ownership exercise limitation and includes signatures dated September 10, 2025.